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Individualised short-term therapy for
adolescents impaired by attention-deficit/
hyperactivity disorder despite previous
routine care treatment (ESCAadol)—Study
protocol of a randomised controlled trial
within the consortium ESCAlife
Julia Geissler1* , Thomas Jans1, Tobias Banaschewski2, Katja Becker3, Tobias Renner4, Daniel Brandeis2,5,6,7,
Manfred Döpfner8,9, Christina Dose8, Christopher Hautmann8,9, Martin Holtmann10, Carolin Jenkner11,
Sabina Millenet2 and Marcel Romanos1
Abstract
Background: Despite the high persistence rate of attention-deficit/hyperactivity disorder (ADHD) throughout the
lifespan, there is a considerable gap in knowledge regarding effective treatment strategies for adolescents with
ADHD. This group in particular often shows substantial psychosocial impairment, low compliance and insufficient
response to psychopharmacological interventions. Effective and feasible treatments should further consider the
developmental shift in ADHD symptoms, comorbidity and psychosocial adversity as well as family dysfunction.
Thus, individualised interventions for adolescent ADHD should comprise a multimodal treatment strategy. The
randomised controlled ESCAadol study addresses the needs of this patient group and compares the outcome of
short-term cognitive behavioural therapy with parent-based telephone-assisted self-help.
Methods/design: In step 1, 160 adolescents aged 12 to 17 years with a diagnosis of ADHD will undergo a treatment
as usual (TAU) observation phase of 1 month. In step 2, those still severely affected are randomised to the intervention
group with an Individualised Modular Treatment Programme (IMTP) or a telephone-assisted self-help programme for
parents (TASH) as an active control condition. The IMTP was specifically designed for the needs of adolescent ADHD. It
comprises 10 sessions of individual cognitive behavioural therapy with the adolescents and/or the parents, for which
participants choose three out of 10 available focus modules (e.g. organisational skills and planning, emotion regulation,
problem solving and stress management, dysfunctional family communication). TASH combines a bibliotherapeutic
component with 10 counselling sessions for the parents via telephone. Primary outcome is the change in ADHD
symptoms in a clinician-rated diagnostic interview. Outcomes are assessed at inclusion into the study, after the TAU
phase, after the intervention phase and after a further 12-week follow-up period. The primary statistical analysis will be
by intention-to-treat, using linear regression models. Additionally, we will analyse psychometric and biological
predictors and moderators of treatment response.
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Discussion: ESCAadol compares two short-term non-pharmacological interventions as cost-efficient and feasible
treatment options for adolescent ADHD, addressing the specific needs and obstacles to treatment success in this group.
We aim to contribute to personalised medicine for adolescent ADHD intended to be implemented in routine clinical care.
Trial registration: German Clinical Trials Register (DRKS), Current Controlled Trial DRKS00008974, http://apps.who.int/
trialsearch/Trial2.aspx?TrialID=DRKS00008974; http://www.drks.de/drks_web/navigate.do?navigationId=trial.HTML&TRIAL_
ID=DRKS00008974; Registered on 28 December 2015.
Keywords: Attention-deficit/hyperactivity disorder, ADHD, Adolescents, Behaviour therapy, Individualised modular
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Background
Childhood attention-deficit/hyperactivity disorder (ADHD)
shows a high tendency to persist into adulthood [1–3],
causes significant social, emotional and academic impair-
ment for the individual and poses a risk of failing to achieve
important educational and psychosocial developmental
goals [4]. Highly comorbid with subsequent adolescent and
adult depression, anxiety and substance abuse, it is also a
predisposing factor for delinquency [5, 6]. ADHD confers a
substantial economic burden with high direct and indirect
costs for society [7, 8]. There is a great need for effective,
feasible and safe treatment strategies. However, the evalu-
ation of treatment response in efficacy studies is typically
based on highly selected patient groups, excluding patients
with poor compliance, most comorbid conditions or com-
mon psychosocial adversity [9].
Psychopharmacological treatment options, especially
psychostimulants and atomoxetine, have been studied
extensively and their efficacy in targeting core symptoms
of ADHD in children and adolescents has been validated
by a large body of research [10–12]. In combination with
psychoeducation, pharmacotherapy is recommended as
treatment of choice for severe and impairing ADHD
symptoms according to national and international guide-
lines [13]. However, the benefits of pharmacotherapy for
adolescents might be reduced in patients with comorbid
disorders [12, 14]. Since medication adherence especially
in adolescence is poor [15, 16], non-pharmacological
treatment options are indispensable.
While there is empirical support for the efficacy of psy-
chosocial interventions in children [17] and adults [18],
cognitive behavioural therapy (CBT) approaches in adoles-
cent ADHD are comparatively scarce. A study assessing
CBT in a group setting found a reduction in ADHD symp-
toms and functional impairment in the treatment group
[19], whereas the usefulness of rational emotive therapy
[20] in adolescents with ADHD could not be confirmed.
Especially controlled studies on individual psycho-
therapy in adolescents are largely lacking [21, 22]. To
date, the available empirical evidence is limited to a
small number of mostly uncontrolled studies and exist-
ing randomised controlled trials (RCTs) comprised
exclusively og multicomponent interventions [12]. An
unpublished Canadian trial [Mongia M, Hechtman L:
Cognitive behaviour therapy in adolescents with attention
deficit hyperactivity disorder: a pilot study, unpublished] re-
ported a 14-session CBT intervention and additional coach-
ing calls as an add-on to psychopharmacological treatment
to result in a reduction of ADHD symptoms as well as im-
provements in self-esteem and level of disability. However,
the small sample size (N = 18) and the lack of a control
group are serious caveats of this study. Another study found
an adaptation of CBT for adult ADHD to adolescents with
residual symptoms under medication to bring about positive
changes on a range of variables such as inattention, medica-
tion adherence, self-esteem, family and academic function-
ing (uncontrolled study [23]). There is some evidence for
the efficacy of a mindfulness training for adolescents and
their parents (uncontrolled study; [24]). The authors re-
ported positive effects on attention and behavioural prob-
lems, executive functioning and parenting while stressing
the need for maintenance strategies to sustain those effects.
Furthermore, there are demonstrated benefits of an
organisational skills training and reinforcement of goal
achievement for older children [25] and for adolescents in
terms of ADHD symptoms and impairment in the frame-
work of extensive summer treatment programmes or
school-based interventions [21, 26], and a reduction of
parent-teen conflicts through family-based interventions
for adolescents and their parents [27]. The Supporting
Teens’ Academic Needs Daily (STAND) programme dem-
onstrated the superiority of a combination of family ses-
sions and group sessions for parents to treatment as usual,
targeting family cooperation by teaching both adolescents
and parents with a focus on improving academic perform-
ance. The authors found improvements in academic func-
tioning and ADHD symptoms [28]. Most recently, Boyer
and colleagues [29–31] showed comparable positive effects
of two non-ADHD-specific CBT interventions, Plan My
Life versus Solution-Focused Treatment, in a randomised
trial. Each intervention arm combined parent and adoles-
cent sessions with motivational enhancement therapy.
The scarcity of (psycho-)therapy research for adoles-
cent ADHD may partly be due to the low compliance
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seen in youths with ADHD [32]. Furthermore, the devel-
opment and evaluation of general treatment strategies is
complicated by the need for individualised treatment
options taking into account the broad comorbid devel-
opment, the shift in ADHD core symptoms, and psycho-
social adversity as well as family dysfunction, e.g. poor
parenting skills and parental mental health problems
[7, 33, 34]. Previous trials conducted by our study
group on treatment options for childhood and adult
ADHD [35–38] and the development of interventions
for adolescents with achievement problems including
ADHD symptoms [39] underscored the feasibility of
successfully conducting clinical trials with adolescent
patients.
In sum, especially individualised treatment plans for
adolescent ADHD need to be developed and evaluated
combining psychosocial and pharmacological interven-
tions in the framework of a multimodal treatment strat-
egy. Treatment must take into account the prevalent
compliance problems of youths with ADHD and must
be individualised with respect to each patient’s constella-
tion of impairment in terms of ADHD symptom expres-
sion and developmental comorbidity.
To address the needs of this group of patients, the
ESCAadol study (Evidence-based stepped care of ADHD:
individualised short-term therapy for adolescents impaired
by ADHD despite previous routine care treatment) was
devised. As adolescent patients with ADHD often present
with comorbid diagnoses and severe impairment, the tar-
get group of ESCAadol are adolescents aged 12–17 years
who are still severely impaired by their ADHD symptoms
according to the Diagnostic and Statistical Manual of
Mental Disorders, Fifth Edition (DSM-5) [40] despite
having been in routine clinical care for at least 6 months.
Based on established interventions, we composed a
short-term, Individualised Modular Treatment Programme
(IMTP), adapting elements of dialectical behaviour therapy
(DBT) for adolescents in general [41] and specifically for
ADHD in adults [42] as well as interventions from the
German treatment manuals for externalising disorders
(THOP, [43]), performance problems in adolescents
(SELBST, [44]), family interventions (PLAN-E, [45]) and
social skills training (FESKO, [46]). We chose interventions
targeting ADHD symptoms and related issues, such as
emotion regulation and self-confidence, in addition to
organisational difficulties, since these are emerging as crit-
ical issues in adolescence. For an outline of the focus areas
included in the programme and their respective thera-
peutic targets, please refer to Table 3.
The IMTP consists of 10 sessions and addresses
deficits in cognitive control, emotion regulation, organ-
isation and planning, conflict management, medication
compliance and parental mental health. The choice of a
short-term treatment accounts for the poor therapy
adherence and motivation often seen in adolescent
ADHD, is supposed to be cost-effective, supports trial
feasibility and facilitates broad dissemination. Different
treatment modules will allow for the adaptation to spe-
cific impairment patterns. This programme will be eval-
uated in a multi-centre, randomised effectiveness study
with an active control condition and blinded observer
ratings of the primary endpoint (change in ADHD symp-
toms). Participants in the active control condition will
be treated with a telephone-assisted self-help (TASH)
programme for parents of adolescents with ADHD.
Although child- or adolescent-centred interventions be-
come more important the older the patient is, parenting
interventions are still recommended for the treatment of
ADHD in adolescents [47]. Self-help interventions have
already been shown to have effects on parent-rated
externalising behaviour problems in preschool- and
school-aged children [48, 49]. Moreover, a pilot-study
using a pre-post design found a large improvement in
parent-rated ADHD symptoms during the TASH inter-
vention used in this study [50]. We chose TASH as the
active control condition since it was designed as a first
step in routine care for unselected patient groups and
we thus assume low to zero effectiveness in our highly
affected and persistent clinical sample that has already
received counselling and treatment. The therapeutic
strategies applied offer sufficient additional support for
the family while the patient remains in routine clinical
care during study participation. Weekly assessments
ensure patients’ safety.
Should this newly developed, highly individualised, short-
term, non-pharmacological intervention prove to be effect-
ive in ameliorating adolescent ADHD symptoms, it will
offer a cost-efficient economic and feasible treatment
option which is designed to create high treatment motiv-
ation for a patient group with frequent compliance issues
and may easily and broadly be implemented in clinical care.
Our study aims to add to the development of treatment
strategies for adolescents and to the evidence base of
treatment approaches. The study will furthermore investi-
gate predictors and moderators of treatment response.
This report presents Version 6 (20 December 2016) of the
study protocol. We followed the Standard Protocol Items
Recommendations for Interventional Trials (SPIRIT)
Statement 2013 (see Additional file 1: SPIRIT 2013 Check-
list: recommended items to address in a clinical trial
protocol and related documents). For the complete World
Health Organization Trial Registration Data Set, please
see Additional file 2.
Our primary hypothesis is a significantly greater
reduction in the primary outcome (ADHD symptoms) in
the IMTP group compared to the active control condi-
tion TASH. On secondary outcomes such as global
impairment, internalising and externalising symptoms,
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we expect greater benefit in the IMTP group compared
to TASH, whereas parenting is expected to improve
more in the parent-focused TASH group. We expect
treatment effects and group differences to remain stable
at follow-up.
Methods/design
Study design and trial flow
Written informed consent for the main trial and all add-
on investigations will be obtained by a senior member of
the study team from all participating adolescents, par-
ents and – if applicable – teachers. The study is de-
signed as a randomised controlled, multi-centre trial. In
step 1 of the study, a planned number of N = 160 partici-
pating adolescents with ADHD will undergo a 4-week
treatment-as-usual (TAU) phase with their attending
physician in order to assess changes in ADHD symp-
toms in routine care. This is a strictly observational
phase, all treatment decisions remain with the attending
physician. At the end of the TAU phase, the study team
will obtain information on which treatments have been
implemented during TAU, followed by an assessment of
ADHD severity and general impairment. Afterwards, an
expected number of N = 140 patients, for whom routine
clinical care has been proven to be insufficient and who
still suffer from severe ADHD, will be randomised either
to the IMTP or to TASH. Treatments will be adminis-
tered over the course of 12 weeks (step 2 of the study).
Measurements will be taken at baseline (T0: screening
of inclusion and exclusion criteria and assessment of
ADHD symptoms; T1: baseline assessment comprising
anamnestic information, pharmacological and non-
pharmacological treatment history, additional informa-
tion on comorbidity and parental self-ratings regarding
child variables and own mental health), after the TAU
phase (T2), after the treatment phase (T3) and 12 weeks
after the end of the treatment (follow-up examination;
T4). Patients failing to meet the severity criterion after
TAU and not having entered the randomisation stage
will also be invited for a follow-up appointment (T4) in
order to monitor their progress in clinical routine treat-
ment. Patients who drop out of the study will be encour-
aged to still participate in the next study visits for data
collection. For an overview of the trial flow, please refer
to Fig. 1. Clinical assessments of ADHD symptoms and
comorbid psychopathology constituting outcome param-
eters will be completed by an experienced clinician who
is blind to the patient’s assignment to treatment condi-
tion, but not to the time point (T0–T4). All randomisa-
tion decisions will be based on those semi-blinded
ratings. All interviews will be recorded and subsequently
a subsample will be rated by a blinded expert in order to
validate the semi-blinded ratings by the clinician. Con-
cerning safety of study participants, unblinding will not
be necessary, since blinding is limited to outcome raters.
Trial sites
Patients will be recruited at six sites across Germany. The
leading centre coordinating the study is the Department
of Child and Adolescent Psychiatry, Psychosomatics and
Psychotherapy at the University Hospital of Würzburg.
Other recruiting centres are the Departments of Child and
Adolescent Psychiatry, Psychosomatics and Psychotherapy
at the University Hospitals of Köln, Hamm, Tübingen,
Mannheim (Central Institute of Mental Health) and
Marburg. Each centre will enrol approximately 25 patients
in order to achieve a total sample size of N = 160 adoles-
cents. Changes in procedures or protocol amendments are
communicated to all study centres via the Clinical Trials
Unit at the University Medical Centre Freiburg and / or
the coordinating centre.
Participants
The study’s target group are adolescents with ADHD
with insufficient improvement of symptoms through at
least 1 year of treatment in routine clinical care. Patients
Fig. 1 ESCAadol trial flow. IMTP = Individualised Modular Treatment Programme, TASH = telephone-assisted self-help, TAU = Treatment as usual,
R = randomisation, T0 = assessment for eligibility, T1–T4 = study visits (outcome parameters)
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will be recruited primarily through the centres’ out-
patient clinics. Further recruitment strategies include
dissemination of information regarding the study at local
conferences, in schools and via contacting paediatricians
and other care institutions. Baseline characteristics will
be collected in an interview to assess basic information
on medical history and sociodemographic information.
Adolescents are considered to be severely affected if
they meet the criterion of high impairment ratings on
the severity of symptoms scale of the Clinical Global
Impression scale (CGI-S ≥ 4, [51]). Severity will be
assessed during screening for general inclusion into the
study and after the TAU phase. Children falling below
the threshold for severe ADHD after TAU will not be
randomised to one of the two behavioural interventions
in step 2, but a follow-up assessment will be carried out.
Patients will be included if they meet all of the eligibility
criteria displayed in Table 1.
Data handling
All legal requirements regarding the protection of per-
sonal data will be met. Each participant will be assigned
a study-specific identification code upon enrolment. All
study data collected from patients will be stored under
that code, ensuring complete pseudonymisation. This
information will not be shared. The only exception is
transmission of contact details to members of the Uni-
versity Hospital Köln who provide the TASH interven-
tion with the participants’ consent. Access to the patient
identification list is limited to the principal investigators
(PIs) and the study coordinators at each site. The Clin-
ical Trials Unit (CTU) Freiburg provides an electronic
remote data entry system (RDE-LIGHT), where informa-
tion is entered by specially trained personnel under the
study code. Built-in security features encrypt all data
before transmission to and from the CTU, thus prevent-
ing unauthorised access to confidential participant infor-
mation. Users entering data into that system will be
registered with the CTU with an individual ID and pass-
word to gain access to the system, thus preventing
unauthorised access to patient data. Data processing at
the CTU is limited to authorised personnel that is famil-
iar with the data handling procedures according to the
study protocol.
Interventions
Individualised modular treatment programme (IMTP)
The IMTP as a focused, short-term, cognitive behav-
ioural intervention consists of 10 weekly sessions of
60 min over a period of 12 weeks (for an overview, see
Table 2). The contents of the opening and the closing
sessions (sessions 1, 2, 9 and 10) are mandatory for all
participants. Sessions 3–8 comprise the strongly indivi-
dualised part of the treatment, where different modules
can be chosen depending on the adolescents’ core prob-
lem areas for a focused and economical treatment of
persistent difficulties. Individualisation is based on clin-
ical data gathered at screening and baseline visits and
goal setting of patient and therapist in sessions 1 and 2.
Treatment is offered in individual sessions because the
required degree of individualisation of treatment cannot
be achieved in a short-term group psychotherapy setting.
Sessions 1 and 2 focus on the establishment of the thera-
peutic relationship, psychoeducation, the development
of an individual concept of the disorder and the selec-
tion of three focus modules for the individualised part of
the therapy. Each module spans two treatment sessions.
Sessions 9 and 10 aim at recapitulating and consolidat-
ing the contents of the previous sessions and planning
the future treatment.
Telephone-assisted self-help (TASH)
As active control treatment, 10 weekly sessions of TASH
[50] are implemented (for an overview, see Table 3).
TASH is based on established principles of behavioural
parent training. It includes strategies aiming at enhan-
cing positive parent-child-interactions and controlling
hyperkinetic and oppositional behaviour (e.g. communi-
cating demands effectively, setting positive and negative
consequences consistently). TASH in the context of this
Table 1 Inclusion and exclusion criteria
Inclusion criteria • Age 12;0 to 17;11 years
• ADHD according to DSM-5 criteria, assessed with a structured clinical interview
• Patient has been in ADHD routine care for a minimum of 6 months (does not have to be the year immediately
preceding the study; routine care defined as treatment aimed at ADHD symptoms as prescribed or provided by
a child and adolescent psychiatrist, psychotherapist or paediatrician)
• No sufficient benefit from previous interventions developed for the treatment of ADHD, i.e. still substantial
impairment (CGI-S≥ 4) under current treatment
• Patients and primary caregiver speak sufficient German for psychotherapy
Exclusion criteria • IQ < 80, assessed with the Wechsler Nonverbal Scale of Ability [101, 102]
• Comorbidity: pervasive developmental disorder, schizophrenia, bipolar disorder, severe depressive episode
• Need for inpatient treatment
• After TAU phase: intensive psychotherapy on a biweekly or more intensive basis
• After TAU phase: psychopharmacological medication which is not constant or not licensed for the treatment
of ADHD or comorbid conditions
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study uses a bibliotherapeutic approach with brochures
specifically developed for parents of adolescents with
ADHD in former trials. A total of eight brochures will
be sent to the parents and will be supplemented by 10
counselling sessions of about 30 min provided by trained
psychologists and pedagogues via telephone in order to
support the parent in the implementation of the recom-
mendations presented in the brochures.
Treatment integrity
Treatment integrity will be established through qualifica-
tion standards for therapists (a university degree qualifying
for training to become a licenced child and adolescent
therapist, currently in training for psychotherapy with
children and adolescents and clinical expertise in the
treatment of ADHD), study-specific therapist training, the
use of manualised treatment programmes, the use of
protocol sheets for treatment documentation, video- and
audio-taping of treatment sessions, adherence and integ-
rity ratings, and structured video-based supervision for
two out of 10 treatment sessions and feedback.
Concomitant treatment is permitted if it is not consid-
ered intensive behavioural therapy (≥ bi-weekly). Psycho-
pharmacological treatment for ADHD is allowed. Changes
in medication during the treatment phase are discouraged
except when clinically necessary. If participants clearly
need additional treatment besides the study interventions,
add-on treatments may be discussed and participation in
the study may be terminated by the study team.
Primary and secondary outcome measures
Primary outcome
The primary endpoint is the change in ADHD symp-
toms from T2 to T3 measured by changes in the total
score of the Diagnose-Checkliste für Aufmerksamkeits-
defizit−/Hyperaktivitätsstörungen (DCL-ADHS), a struc-
tured DSM-5-based clinical interview. It comprises 18
items assessing ADHD symptoms, and five items asses-
sing functioning and psychological strain and shows
good internal consistency (Cronbach’s α = 0.89–0.95)
and high validity [52–54]). All items are rated on a 4-
point scale (0–3; symptom present if ≥2). For ESCAadol,
the interview is conducted with parents and adolescents
in a joint session.
Secondary outcomes
The most important secondary endpoint is the change
on the Clinical Global Impression Scale (CGI, [51]) from
Table 2 Overview of the Individualised Modular Treatment Programme (IMTP) modules
Title Target Participants
A Organisation is key Organisational skills and planning A
B Full concentration Distractibility and procrastination A
C The Courage Module Dysfunctional thinking A
D The Emotion Module Emotion regulation A
E Less stress – greater satisfaction Problem solving, stress management A
F The Medication Module Medication management A
G Thrill seekers Harmful substance (ab)use A
H Improving family communication Dysfunctional communication P + A
I Parent training Parental competence P (+A)
J Keeping an eye on own well-being Parental mental health P
A = adolescent, P = parent
Table 3 Overview of telephone-assisted help programme (TASH) brochures for parents
Title Target
1 ADHD in adolescence Psychoeducation regarding ADHD symptoms, associated problems, the courses
of ADHD and treatment alternatives
2 Analysing and tackling problems Analysing problems and coercive parent-child interactions; focus on strengths
3 ‘With each other, not against each other’ Escaping coercive parent-child interactions; positive interactions; rules of
communication
4 Re-evaluating rules Reconsidering and defining rules; agreements for solving frequent conflicts
5 Joint negotiations Holding constructive problem talks with adolescents
6 Planned consequences, step 1 Making clear demands and reinforcing positive behaviour
7 Planned consequences, step 2 Adequate negative consequences and behaviour contracts
8 Regenerating and looking to the future Parental well-being and future prospects of the parents
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T2 to T3 and from T2 to T4. It measures the severity of
the disease (CGI-S) and the general improvement
through treatment (CGI-I). The assessment takes place
after a short clinical interview. CGI-S and CGI-I are
evaluated on a 7-point scale, with higher scores indicat-
ing a greater severity or impairment, respectively. Des-
pite conflicting findings with regard to reliability and
validity, the CGI is widely used in clinical trials as an
outcome parameter. The CGI-I shows good interrater
reliability (0.65–0.92) [55] and an intra-class correlation
coefficient of 0.91 [56].
Further secondary endpoints are changes in patient-,
parent- and teacher-rated ADHD and symptoms of op-
positional defiant disorder (ODD) and conduct disorder
(CD), ADHD-related functional impairment and quality-
of-life, internalising and externalising symptoms and
parenting from T2 to T3, and T2 to T4:
ADHD and ODD/CD symptoms
Parents, teachers and patients rate the severity of all
of the core symptoms of ADHD and a core set of
symptoms of CD on a 4-point scale on the question-
naires Fremdbeurteilungsbogen für Aufmerksamkeits-
defizit-/Hyperaktivitätsstörungen (FBB-ADHS; parent
report Cronbach’s α = 0.91–0.94; teacher report Cronbach’s
α = 0.87–0.93), Selbstbeurteilungsbogen für Aufmerk-
samkeitsdefizit-/Hyperaktivitätsstörungen (SBB-ADHS;
self-report; Cronbach’s α = 0.79–0.89), Fremdbeurtei-
lungsbogen für Störungen des Sozialverhaltens (FBB-
SSV; parent report Cronbach’s α = 0.67–0.91; teacher
report Cronbach’s α = 0.69–0.92) and Selbstbeurtei-
lungsbogen für Störungen des Sozialverhaltens (SBB-
SSV; self-report [52]; Cronbach’s α = 0.65–0.89). The
Diagnose-Checkliste für Störungen des Sozialverhaltens
(DCL-SSV) will be completed by a semi-blinded clinician
rater based on an interview with parents and adolescents
[52]. This interview also shows good internal consistency
(Cronbach’s α = 0.68–0.88).
Functional impairment and quality of life
The Weiss Functional Impairment Rating Scale (WFIRS-
P, [57, 58]) assesses impairment specifically associated
with ADHD. Parents rate 40 items on the dimensions
family, learning and school, life skills, child’s self-concept
and social activities on a 4-point scale. This interview
also possesses good internal consistency (Cronbach’s α >
0.7), test-retest reliability (r > 0.7) and validity [59, 60].
The Health-Related Quality of Life Questionnaire for
Children and Young People (KIDSCREEN-10, [61, 62])
comprises 10 items and measures the parent- and child-
rated subjective health and well-being of children and
adolescents on a 5-point scale. The authors report good
internal consistency (Cronbach’s α = 0.82) and test-retest
reliability (r = 0.73).
Internalising and externalising symptoms
The Child Behaviour Checklist (CBCL/6-18R) is a parent
questionnaire assessing the behavioural and emotional
problems of children and adolescents with 113 items on
a 3-point scale. The instrument shows good reliability
for most scales (rtt > .80) and good validity [63–65].
Parenting Rating Scales
Perceived parenting sense of competency concerning diffi-
cult parenting situations is assessed with the questionnaire
Verhalten in Risikosituationen (VER [66]). The first 14
items describe typical situations (e.g. going shopping).
Thirteen other items describe child behaviour (e.g. ‘refuses
to eat’). On a 4-point scale, parents can state how well they
can manage the situations. Positive parenting will be
assessed with the Fragebogen zum Erziehungsverhalten
(FZEV), which has been devised using items from the Posi-
tive Parenting subscale of the Parent Practices Scale (PPS
[67]) among others. It consists of 13 items which measure
positive, reinforcing and encouraging parental behaviour
such as praise, playing together, attention and physical af-
fection on a 4-point scale. Both instruments show good in-
ternal consistency [67, 68] and have been used in multiple
intervention studies; e.g. [69]. Negative parenting is mea-
sured by a short version of the negative parenting subscale
of the German questionnaire Fragebogen zum positiven
und negativen Erziehungsverhalten (FPNE [70]. The ques-
tionnaire consists of 13 items with a 4-point scale.
Therapy preconditions and process variables
To gain insight into motivational aspects for treatment
as well as treatment quality, measures of treatment ex-
pectation, motivation and satisfaction ratings of partici-
pating parents and the adolescents are included.
Therapists will rate their treatment expectation as well as
provide data regarding treatment integrity and adherence.
Furthermore, we will examine changes in the concentra-
tion of genetic transcripts such as micro-RNAs and
mRNAs in peripheral tissue as potential biological corre-
lates of response to therapy pre- and post-treatment.
Predictors and moderators of therapeutic outcome
Predictors – Psychometric data
As possible predictors of the primary treatment out-
come, we will collect data with regard to sociodemo-
graphic information (e.g. age and sex, IQ, familial
psychosocial risk factors) and treatment expectation of
the parent, adolescent and therapist.
Furthermore predictors comprise child temperament
(Junior Temperament and Character Inventory, JTCI; par-
ent- and self-report; test-retest reliability r = 0.65–0.87;
Cronbach’s α = 0.79–0.85; validity [71–73]), emotional dys-
regulation (adolescent self-report on the German question-
naires Fragebogen zur Erhebung der Emotionsregulation bei
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Kindern und Jugendlichen, FEEL-KJ; test-retest reliability
r = 0.62–0.81; Cronbach’s α = 0.69–0.91; validity [74, 75]),
and social responsiveness of the child (Social Responsiveness
Scale, SRS; test-retest reliability r = 0.72–0.91; Cronbach’s
α = 0.91–0.97; validity [76–79]), problem behaviour on vari-
ous domains according to the Youth Self Report Scale (YSR;
good test-retest reliability internal consistency and validity
[80–82]) and irritability (Affective Reactivity Index, ARI;
test-retest correlation r = 0.88 for parent-report and 0.29
for self-report; Cronbach’s α = 0.89 for parent-report
and 0.90 for self-report [83]; validity [84]).
Furthermore we assess parental variables such as ADHD
(ADHS-Selbstbeurteilungsskala ADHS-SB: test-retest reli-
ability r = 0.78–0.89; Cronbach’s α = 0.72–0.9, validity [85];
Wender Utah Rating Scale – deutsche Kurzform, WURS-
K: test-retest reliability r = 0.9; Cronbach’s α = 0.91, validity
[85, 86]), depression, anxiety and stress (Depression Anx-
iety Stress Scales, DASS; Cronbach’s α = 0.89–0.96, test-
retest realability r = 0.71–0.81, validity [87, 88]) as well as
parental coping with anger (Elternfragebogen zum Umgang
mit Ärger, FB-Ä [89]) with self-report questionnaires. As a
further predictor, clinical rating scores on psychiatric
comorbidity in the child obtained with the structured
screening interview Diagnose-Checkliste zum Screening
psychischer Störungen (DCL-SCREEN, [52]) will be used.
In this study, the DCL-SCREEN will be used to screen for
symptoms of autism spectrum disorders, depressive disor-
ders, anxiety disorders, obsessive-compulsive and related
disorders, tic disorder, somatoform and related disorders,
motor and language disorders, specific learning disorders
and elimination disorders. In case of clinical symptoms
emerging in the DCL-SCREEN, we will use the diagnostic
checklist for the particular disorder from the Diagnostik-
System für psychische Störungen nach ICD-10 und DSM-5
für Kinder- und Jugendliche (DISYPS-III, [52]) for an
extensive assessment based on DSM-5 diagnostic criteria.
Predictors – Biological variables
The selected predictors will be obtained through assess-
ments with electroencephalography (EEG; spontaneous
and event-related EEG-recordings), magnetic resonance
imaging (structural MRI, diffusion tensor imaging and
functional MRI) as well as transcranial sonography (TCS).
Furthermore, blood and saliva samples will be collected
from all participants before (T1) and after treatment (T3).
EEG and MRI measurements are limited to the subgroup
receiving the IMTP and will be performed following ran-
domisation. TCS measurements will be performed at any
time during the study with all patients who provide
informed consent.
TCS is a non-invasive method for the visualisation of
deep brain structures through the intact skull. Ultrasound
waves are reflected depending on tissue composition,
resulting in different echogenicity of nuclei and ventricular
system. Of particular interest is the mesencephalic scan-
ning plane including brainstem, substantia nigra and
raphé nuclei. In children, ADHD-associated hyperecho-
genicity of the substantia nigra has consistently been
reported and it has been proposed as a potential biological
marker for ADHD [90, 91]. TCS can aid differential diag-
nosis (e.g. in movement disorders, [92]) and has shown
promise in the prediction of treatment response in psychi-
atric disorders in adult patients [93, 94]. As of yet, no
study has explored the possibility of using TCS to predict
the effectiveness of non-pharmacological interventions. In
the context of our study, the TCS-based predictor of treat-
ment outcome will be the size of the echogenic area of the
substantia nigra, which has been shown to be associated
with the disorder [90, 91].
Genetic material will be extracted from blood and saliva
samples. We will analyse genetic variants in candidate
gene systems for their predictive value regarding an indi-
vidual’s response to different therapeutic interventions.
The EEG-based predictors consist of the frequency pro-
file at rest (spontaneous theta-band and alpha-band activ-
ity) and the strength of preparatory cognitive activity
(contingent negative variation amplitude), which explain
nearly 30% of the variability in behavioural improvement
following neurofeedback treatment [95]. To test the
mechanisms of improvement underlying the IMTP, EEG
recordings are repeated following this treatment in step 2.
The changes in brain electric activity, i.e. the hypothesised
reduction of resting theta-activity and increased contin-
gent negative variation activity, will be treated as add-
itional secondary outcome measures in this subgroup.
The MRI-based predictors consist of the integrity
(fractional anisotropy) of the fronto-striatal connection
and of volumetric grey matter density of the implicated
dorsolateral-prefrontal und striatal regions.
As neuropsychological predictors we include four
computer-based experimental paradigms: The continu-
ous performance task (CPT-OX, [96]) measures selective
attention and impulsive behaviour by requiring partici-
pants to withhold a prepared response through inhibi-
tory response control. The monetary incentive delay task
(MID, [97, 98]) is a paradigm to study reward anticipa-
tion and reward feedback in an event-related task with
three task conditions (no win; small win; big win). The
Stop Signal Task (SST, [98, 99]) is used to study inhibi-
tory control. The task composes go-trials and stop-trials.
A tracking algorithm changes the time interval between
go-signal and stop-signal onsets according to each sub-
ject’s performance on previous trials.
Moderators
For the investigation of moderators of treatment out-
come, we will examine the influence of age, sex, socio-
economic status, ADHD symptom severity, comorbid
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symptoms, intelligence, parental mental health (paren-
tal depression, anxiety and stress assessed by self-
ratings on the DASS; parental ADHD assessed with the
ADHD-SB).
For an overview of all measures used at individual
time points throughout the study, please refer to Fig. 2.
Rater training
Semi-blinded clinicians and blinded raters will be trained
in the assessment of ADHD, CD and comorbid condi-
tions with the DCL-ADHS and DCL-SSV. After viewing
and scoring a video recording of a diagnostic interview
using the DCLs, their ratings will be compared to a ‘gold
standard’ established by the authors of the DISYPS-III.
The first three interviews with participants will be super-
vised by a certified rater. A reliability analysis will be
conducted at the end of the study.
Randomisation procedure
Central randomisation with a 1:1 treatment ratio will be
performed by the CTU at the University Medical Centre
Freiburg via fax, using block randomisation with variable
block length to guarantee concealment of randomisa-
tion. Randomisation will be stratified by centre. The
randomisation request form contains the following infor-
mation: study-specific patient identification number, year
of birth and the confirmation of ADHD > cut-off. The
central randomisation office will review the patient’s de-
tails on the randomisation fax. If data on the fax are
complete and appropriate, the randomisation will be
performed by the central randomisation office. The
patient will be entered in the randomisation list at the
randomisation office, and the randomised treatment arm
will be sent to the investigator by fax. The returned ran-
domisation fax will contain the information entered by
the investigator complemented by the information about
the randomised treatment (IMTP or TASH).If the details
on the randomisation fax appear to be incomplete or
implausible, the central randomisation office will send a
query fax to the investigator for clarification.
Monitoring and safety
The monitoring is performed by the clinical research
associates (CRAs) of the CTU. Adapted monitoring will
be done according to Good Clinical Practice (ICH-GCP)
and standard operating procedures (SOP) to verify that
patients’ rights and well-being are protected, reported
trial data are accurate, complete and verifiable from
source documents and that the trial is conducted in
compliance with the currently approved protocol/
amendment, with ICH-GCP and with the applicable
regulatory requirements to ensure safety and integrity of
clinical trial data. Prior to the trial, a pre-trial visit by
phone, a site initiation visit at each site and an
investigators’ meeting are conducted in order to train
and introduce the investigators and their staff to the trial
protocol, essential documents and related trial specific
procedures, ICH-GCP and national/local regulatory re-
quirements. Additional training via telephone may be
employed if necessary.
During the trial, the monitor will visit the site regularly
depending on the recruitment rate and quality of data.
During these on-site visits, the monitor verifies that the
trial is conducted according to the trial protocol, trial spe-
cific procedures, ICH-GCP and national/local regulatory
requirements. The presence of signed informed consents,
the eligibility of patients, primary endpoint, treatment
compliance and documentation will be verified by the
monitor. The monitor is also performing source data veri-
fication to ensure that clinical trial data are recorded and
documented in the source data and case report forms
(CRFs) are complete and accurate. Extent of source data
verification and monitor visit frequency will be adapted
for individual sites in case of lack of data quality or a high
number of protocol violations.
An independent Data Monitoring Committee (DMC)
is formed by Prof. Dr. med. H. J. Freyberger, Prof. Dr.
med. A. Rothenberger and Prof. Dr. med. J. Schmitt. The
DMC will advise the trial sponsor on patient safety and
measures to ensure the credibility and integrity of the
ongoing trial.
Stopping rules
Stopping rules for an individual patient include with-
drawal of informed consent of parents / guardians or the
patient, need for inpatient treatment or other reasons
affecting the patient’s well-being in the case of continued
trial participation or need for a different kind of treat-
ment for health reasons according to the judgement of
the attending physician. The Ethics Committee will be
informed immediately in case of severe adverse events
during the conduct of the trial. Global stopping rules for
the trial or closing of a centre include emerging of data
leading to a revision of the risk-benefit ratio, on-going
failure of recruitment or repeated violations of the study
protocol or standard GCP rules. For a decision on
the termination of the trial or of closing a centre,
agreement between PI, site investigators, DMC mem-
bers, responsible Ethical Committee and the CTU
Freiburg is intended.
Proposed sample size and power calculations
The calculation of the sample size (software: STPLAN
Version 4.3) is based on the primary endpoint ‘change in
total score of DCL-ADHS from T2 (after TAU-
stabilisation) to T3 (after experimental or control treat-
ment; 12 weeks)’ using the two-sided t test with a power
of 80% at a significance level of 5%. Studies on
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Fig. 2 (See legend on next page.)
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psychosocial interventions on the treatment of ADHD
report effect sizes of about d = 0.8 [100], where d de-
notes the difference in the change score between the
two randomised groups in standard deviation units.
However, we have chosen a smaller effect size to calcu-
late the sample size because recent meta-analyses
referring to less biased outcome criteria such as assess-
ments by clinicians report smaller effects of non-
pharmacological interventions for the treatment of
ADHD [22]. Furthermore, these effect sizes are based on
trials with mostly waiting control group, thus, we expect
our effects to be smaller. Additionally, in our highly af-
fected clinical sample treatment effects might be less
pronounced. A smaller effect size also accounts for the
fact that the planned intention-to-treat approach might
dilute the true expected effect – patients who discon-
tinue therapy will be included in the primary analysis.
We assume low to zero pre-post effects within our con-
trol group. Therefore, an effect size of d = 0.5 between
groups seems realistic, and it is considered to be still
clinically relevant. To detect a difference assuming the
true effect size is d = 0.5, 64 patients with non-missing
data per group are required (critical t = 1.98, df = 126).
In order to account for the possibility that a few pa-
tients (8%) will have incomplete data at T3, in total
140 patients will have to be randomised. Studies on
psychosocial interventions in ADHD children and
their parents report attrition rates ranging from 5 to
20%. The study by Antshel et al. on CBT for adoles-
cents with ADHD-symptoms unresolved by medica-
tion fits best with our intended sample. In this trial
CBT adherence was good (all patients attended 13–16
sessions with half of the patients never missing an ap-
pointment and half missing between one and three ap-
pointments). Therefore, a rate of 8% with incomplete
data at T3 seems conservative [23].
The sample size will provide sufficient power to handle
the described imponderabilia of dropouts and incom-
plete data. Based on clinical experience we assume that
about 10% of the patients will be improved after TAU-
stabilisation, and, therefore, estimate that N = 160 need
to be recruited at baseline to attain 140 randomisations.
Based on our prior research on clinical trials in ADHD
[33] we expect a 30% to 40% rate of screening failures.
Thus, about N = 250 patients will need to be screened
for study participation.
Statistical analyses
All statistical programming for analysis will be per-
formed with the Statistical Analysis System (SAS®).The
primary analysis is based on an intention-to-treat
approach. This means that the patients will be analysed
in the treatment arms to which they were randomised,
irrespective of whether they refused or discontinued the
treatment or whether other protocol violations are
revealed. The per-protocol (PP) population is a subset of
the Full Analysis Set (FAS) and is defined as the group
of patients that had no major protocol violations, re-
ceived a predefined minimum dose of the treatment and
underwent the examinations required for the assessment
of the endpoints at relevant, predefined times. The ana-
lysis of the PP population will be performed for the pur-
pose of a sensitivity analysis.
Safety analyses will be performed in the safety popula-
tion. Patients in the safety population are analysed as
belonging to the treatment arm defined by treatment re-
ceived. Patients are included in the respective treatment
arm, if treatment was started / if they received at least
one dose of trial treatment.
Analysis of primary endpoint
The primary statistical analysis will be by intention-to-
treat, so that all randomised patients will be analysed
according to their allocated arm. Changes in the DCL-
ADHS score from T2 to T3 and T2 to T4, respectively,
will be evaluated in a linear regression model including
treatment, centre, visit and the respective T2-baseline
DCL-ADHS. Further covariates predictive of missingness
(See figure on previous page.)
Fig. 2 Overview of outcome measures, predictors and eligibility criteria. Rater: A = adolescent, B = blind rater, C = clinician, F = father, M =mother,
P =parents, T = teacher, Th = therapist; Variable type: I = inclusion criterion, O =outcome variable, P =predictor, Q = variable for quality control; Interventions,
IMTP = Individualised Modular Treatment Programme, TASH = telephone-assisted self-help; measures: ADHS-SB =ADHS-Selbstbeurteilungsskala, ARI =Affective
Reactivity Index, CBCL =Child Behaviour Checklist, CGI =Clinical Global Impression, DASS =Depression Anxiety Stress Scales, DCL-ADHS =Diagnose-Checkliste
für Aufmerksamkeitsdefizit−/Hyperaktivitätsstörungen, DCL-SCREEN = Diagnose-Checkliste zum Screening psychischer Störungen, DCL-SSV =
Diagnose-Checkliste für Störungen des Sozialverhaltens, EEG = electroencephalogram, FAI = Family Adversity Index, FB-Ä = Elternfragebogen
zum Umgang mit Ärger, FBB-ADHS = Fremdbeurteilungsbogen für Aufmerksamkeitsdefizit-/Hyperaktivitätstörungen, FBB-SSV = Fremdbeurteilungsbogen
für Störungen des Sozialverhaltens, FEEL-KJ = Fragebogen zur Erhebung der Emotionsregulation bei Kindern und Jugendlichen, FPNE = Fragebogen zum
positiven und negativen Erziehungsverhalten, FZEV = Fragen zum Erziehungsverhalten, JTCI = Junior Temperament and Character Inventory,
KIDSCREEN-10 = The Health-Related Quality of Life Questionnaire for Children and Young People, MID = Monetary-Incentive-Delay-Task,
MRI = magnetic resonance imaging, SBB-ADHS = Selbstbeurteilungsbogen für Aufmerksamkeitsdefizit-/Hyperaktivitätstörungen, SBB-SSV =
Selbstbeurteilungsbogen für Störungen des Sozialverhaltens, SRS = Social Responsiveness Scale, SST = Stop Signal Task, TCS = transcranial
sonography, VER = Verhalten in Risikosituationen, WFIRS-P =Weiss Functional Impairment Rating Scale, WURS-k =Wender Utah Rating Scale – short
version, YSR = Youth Self Report Scale. *only for patients randomised to one of the two treatment conditions
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will be included based on a pre-specified selection strat-
egy to correct for potential bias arising from missing
data. The primary treatment comparison of the change
score at T3 will be based on least-squares means with a
two-sided 95% confidence interval. Other possibly rele-
vant covariates may be considered as well. Subgroup
analyses will be conducted in an exploratory manner by
inclusion of interaction terms in the linear regression
model. They will focus on the analysis of patients’ and
parents’ comorbidities. In addition, gender effects will be
investigated as prognostic and predictive factors.
Analysis of secondary endpoints
Secondary endpoints will be analysed descriptively in a
similar fashion as the primary outcome, using regres-
sion models as appropriate for the respective type of
data. Treatment effects will be calculated with two-
sided 95% confidence intervals. Details are specified in
a statistical analysis plan which was prepared before
the inclusion of the first patient. For all endpoint
scores the change between T2-baseline and T3, and T2
and T4 will be evaluated. The analysis of the change
between T2-baseline and T3 will be done similar to
the analysis of the primary endpoint for continuous
measurements. The difference in CGI between T2 and
T3 will be analysed using the Mann-Whitney-U-test.
The difference in CGI between T2 and T4 will be ana-
lysed using a Kruskall-Wallis test. Possible moderators
and mediators of the DCL-ADHS score will be ana-
lysed using linear regression.
Discussion
Adolescence is a crucial period for determining
patients’ life trajectories in terms of mastering educa-
tional and psychosocial developmental tasks. However,
in adolescents with ADHD motivation to seek treat-
ment, treatment adherence and compliance are often
lacking [15]. Furthermore, comorbidities gain import-
ance; however, this is often not adequately addressed
by standard psychological and pharmacological inter-
ventions for ADHD. Psychopharmacological treatment
is of limited effect in this age group [12, 14]. Thus,
there is a strong need for effective psychosocial inter-
ventions that generate high motivation and compli-
ance and that also take into account non-core ADHD
symptoms, such as emotion regulation and self-image,
as well as comorbidity. Considering the limited empir-
ical evidence for non-pharmacological treatment
options of ADHD in adolescence, ESCAadol is con-
ceptualised as a RCT for the evaluation of an innova-
tive short-term CBT programme tailored to the needs
of ADHD patients aged 12 to 17 years. One limitation
of the trial is the absence of a waiting control group
under routine clinical care. However, considering the
limited number of potential participants in that age
group, limiting the study design to two groups seemed
necessary for obtaining a sufficient sample size. There-
fore, we decided on an active control treatment to
provide at least minimal support for adolescents in
that crucial period for ethical reasons. Furthermore,
demonstrating superiority of a short-term behavioural
therapy programme over an active control condition
presents a more rigorous test of the treatment efficacy
than comparing it to no intervention. This RCT will
be conducted in accordance with the highest stan-
dards of psychotherapy research, employing blinded
outcome ratings and relying on power analyses to en-
sure adequate statistical power to detect effects. All
raters and therapists receive special training prior to
being involved with the study. The main treatment
comprises a manualised therapy. Adherence to the
manual will be checked. We compare the efficacy of
this adolescent-centred intervention with a parent-
centred telephone-assisted self-help programme as an
active control treatment. Taking into account the
broad spectrum of clinical presentations, comorbidi-
ties and environmental factors, the study furthermore
aims at achieving a sample size that allows for the
identification of predictors of treatment response
across different modalities (psychometric variables,
neuropsychological tests, brain functioning during rest
and cognitive activity, structural brain imaging and
biomarkers in blood and saliva). Results aim to fill a
knowledge gap in the treatment of adolescents with
ADHD who do not benefit from routine clinical care
and at evaluating a cost-effective and feasible indivi-
dualised treatment that can easily be implemented in
routine clinical practice within the context of a perso-
nalised medicine approach.
Trial status
Recruitment for this trial is ongoing.
Additional file
Additional file 1: SPIRIT 2013 Checklist: recommended items to address
in a clinical trial protocol and related documents*. (DOC 126 kb)
Additional file 2: World Health Organization Trial Registration Data Set.
(DOC 17.4 kb)
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Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), Classification and
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Association; EEG: Electroencephalography or electroencephalogram;
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negativen Erziehungsverhalten ’ to measure negative parenting practices;
FZEV: German questionnaire ‘Fragen zum Erziehungsverhalten’ to measure
positive, reinforcing and promotive parenting practices; ICH-GCP: Good Clinical
Practice; IMTP: Individualised Modular Treatment Programme, short-term behav-
iour therapy programme comprising 10 sessions specifically developed for adoles-
cents with ADHD; IQ: Intelligence quotient; JTCI: German questionnaire ‘Junior
Temperament und Charakter Inventar’ to assess child personality; KIDSCREEN-
10: The Health-Related Quality of Life Questionnaire for Children and Young
People; MID: Monetary incentive delay task; MMRM: Mixed-effects model for
repeated measures; MRI: Magnetic resonance imaging; ODD: Oppositional defiant
disorder; PP: Per protocol population; RCT: Randomised controlled trial;
SBB-ADHS: Selbstbeurteilungsbogen für Aufmerksamkeitsdefizit-/
Hyperaktivitätstörungen; SBB-SSV: Selbstbeurteilungsbogen für Störungen
des Sozialverhaltens; SOP: Standard operating procedures; SRS: Social
Responsiveness Scale; SST: Stop Signal Task; STAND: Supporting Teens’
Academic Needs Daily; Step 1: Observational period of 4 weeks; Step
2: Main treatment period with a duration of 12 weeks; T0: Screening at the
beginning of the study to assess inclusion and exclusion criteria; T0/T1: To
indicate overlap in diagnostic procedure of T0 and T1 assessment;
T1: Assessment at baseline before Step 1; T2: Assessment at the end of
Step 1 and before beginning of Step 2 intervention; T3: Assessment at the
end of Step 2 intervention; T4: Follow-up assessment 12 weeks after the
end of Step 2 intervention; TASH: Telephone-assisted self-help for parents;
TAU: Treatment as usual, observation phase between T1 and T2;
TCS: Transcranial sonography; VER: German questionnaire ‘Verhalten in
Risikosituationen’ to assess the perceived ability to solve difficult parenting
situations; WFIRS-P: Weiss Functional Impairment Rating Scale – parent
report; WNV: Wechsler Nonverbal Scale of Ability, tool for assessment of
the inclusion criterion intelligence level; WURS-K: Wender Utah Rating
Scale, short version; YSR: Youth Self Report Scale
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